We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Spinal Cord Neuromodulation for SCI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02313194
Recruitment Status : Active, not recruiting
First Posted : December 9, 2014
Last Update Posted : November 24, 2021
Information provided by (Responsible Party):
Daniel Lu, MD, PhD, University of California, Los Angeles

Brief Summary:
This study is designed to assess the strategy of using spinal cord stimulation to improve the ability to move in spinal cord injured humans.

Condition or disease Intervention/treatment Phase
Cervical Spinal Cord Injury Tetraparesis Tetraplegia Device: Epidural Stimulation Drug: Buspirone Phase 1 Phase 2

Detailed Description:
An epidural stimulation device will be tested to determine if motor function can be improved.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Enabling Forelimb Function With Agonist Drug and Epidural Stimulation in SCI
Study Start Date : July 2013
Estimated Primary Completion Date : December 30, 2022
Estimated Study Completion Date : December 30, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Buspirone

Arm Intervention/treatment
Experimental: Stimulation
Determine if epidural stimulation can improve motor function.
Device: Epidural Stimulation
Determine if epidural stimulation can improve motor function

Drug: Buspirone
Determine if the pharmacological agent in combination with the stimulator can improve motor function.

Primary Outcome Measures :
  1. Assessment of arm/hand function [ Time Frame: 24 months ]
    Formal motor testing

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Stable medical condition without cardiopulmonary disease or dysautonomia that would contraindicate hand/arm movement
  2. No severe cardiopulmonary diseases such as severe bradycardia, severe autonomic dysreflexia, and/or Chronic Obstructive Pulmonary Disease.
  3. No painful musculoskeletal dysfunction, unhealed fracture, contracture, pressure sore, or infection that might interfere with upper extremity training
  4. No clinically significant depression or ongoing drug abuse
  5. No current anti-spasticity medication regimen
  6. Non-progressive SCI above C5
  7. Must not have received botox injections in the prior six months
  8. Be unable to grip or move independently
  9. Be at least one-year post injury
  10. Must be at least 18 years of age
  11. Segmental reflexes remain functional below the lesion
  12. Female subjects of child-bearing potential must not be pregnant and must be using a medically acceptable method of contraception
  13. No current implant(s) of neurostimulators, cardiac pacemakers, defibrillators, shunts, stents, or aneurysm clips, and must have no future exposure to diathermy following implantation
  14. No coagulopathy, cardiac risk factors, or other significant medical risk factors for surgery
  15. Must not be involved in another clinical trial
  16. Must not have disorders or conditions that would require MRI monitoring

Exclusion Criteria:

None as long as inclusion criteria are met.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02313194

Layout table for location information
United States, California
Los Angeles, California, United States, 90095
Sponsors and Collaborators
University of California, Los Angeles
Layout table for investigator information
Principal Investigator: Daniel C Lu, MD PhD University of California, Los Angeles
Layout table for additonal information
Responsible Party: Daniel Lu, MD, PhD, Associate Professor, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT02313194    
Other Study ID Numbers: 12-001416
First Posted: December 9, 2014    Key Record Dates
Last Update Posted: November 24, 2021
Last Verified: November 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Cord Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries
Neurologic Manifestations
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action